Background:
A sarcoma is a rare cancer. It grows in the body's connective tissue. Sarcomas in the brain
and central nervous system are especially rare. The drug Sunitinib has been approved in many
countries for treating other types of rare or advanced cancers. These include kidney,
pancreas, and bowel cancer. Researchers want to see if it can help people with sarcomas of
the central nervous system.
Objective:
To study the effects of Sunitinib on gliosarcomas or sarcomas of the central nervous system.
Eligibility:
Adults ages 18 and older with a gliosarcoma or sarcoma of the central nervous system
Design:
Participants will be screened with the following tests. Some may be done as part of their
regular cancer care:
Medical history
Medication review
Physical exam
Blood, heart, and pregnancy tests
Cranial scans to locate and measure their tumor
Participants will take Sunitinib by mouth every day for 2 weeks and then take none of the
drug for 1 week. These 3 weeks equal 1 cycle.
Participants will have 2 study visits in cycle 1. They will have 1 visit in all other cycles.
They will answer questions about quality of life and repeat some screening tests.
Participants will take their blood pressure at home weekly. They keep a diary of each dose of
Sunitinib and blood pressure reading.
Participants can choose to share data about their physical activity levels and quality of
sleep. These participants will wear a small, portable watch-sized accelerometer device on the
wrist for 6 cycles.
About 1 month after their last study drug dose, participants will have a final study visit.
They will have a physical exam, blood tests, and scans.
Additional locations may be listed on ClinicalTrials.gov for NCT03641326.
See trial information on ClinicalTrials.gov for a list of participating sites.
Background:
- Gliosarcoma and primary central nervous system (CNS) sarcomas are malignant brain tumors
uniformly associated with poor outcome.
- There are no known effective medical therapies for these cancers.
- Sunitinib is an orally administered small molecule that inhibits signaling of multiple
receptor tyrosine kinases including those known to be activated in CNS sarcomas.
Objectives:
To determine the anti-tumor effect of sunitinib in recurrent gliosarcomas and primary CNS
sarcomas as assessed by objective response rate (ORR).
Eligibility:
- Patients with histologically proven gliosarcoma and primary CNS sarcoma at disease
relapse after failing standard therapy (surgery and irradiation).
- Tumor tissue blocks or 15 unstained slides should be available
- Subjects must be greater than or equal to 18 years old.
- Karnofsky performance status of greater than or equal to 60
- Patients must have adequate organ function.
- Patients must not have received tyrosine kinase inhibitor(s) in the past.
Design:
- This is a prospective, single institution, single arm, multi-cohort phase II study of
sunitinib in subjects with recurrent gliosarcoma and primary CNS sarcoma that have
failed prior surgery and irradiation (unless radiation therapy was contraindicated).
- Subjects will be classified into three cohorts: 1) Primary gliosarcoma; 2) Secondary
gliosarcoma; 3) Primary CNS sarcoma. Cohort expansion will be carried out at indication
of promising response.
- Sunitinib will be administered orally using a continuous schedule at 50 mg per day (with
dose adjustments allowed for toxicity) for 2 weeks with 1 week off to constitute a
3-week cycle until disease progression or development of intolerable side-effects.
- Toxicity will be assessed every cycle by Common Terminology Criteria in Solid Tumors
(CTCAE) version 5.0.
Lead OrganizationNational Cancer Institute
Principal InvestigatorMark R. Gilbert
